Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

作者：Frank Cools, Saverio Virdone, J.P.S. Sawhney, Renato D. Lópes, Barry Jacobson, Juan I. Arcelus, Richard Hobbs, Harry Gibbs, Jelle C L Himmelreich, Peter MacCallum, Sebastian Schellong, Sylvia Haas, Alexander G.G. Turpie, Walter Ageno, Ana Thereza Rocha, Gloria Kayani, Karen S. Pieper, Ajay K. Kakkar, Ajit Avhad, Murillo de Oliveira Antunes, Ana Thereza Rocha, Jesus Gonzales Lama, Atul Abyankar, Adrian Kormann, Louis van Zyl, Upendra Kaul, Frances Adams, Ivan Aloysius, Matthew Capehorn, Pradeep Kumar, Rajesh Mahajan · 发表于：The Lancet Haematology · 年份：2022 · DOI：10.1016/s2352-3026(22)00173-9 · 被引用次数：61 · 研究领域：Heparin-Induced Thrombocytopenia and Thrombosis、Intramuscular injections and effects、COVID-19 Clinical Research Studies